– In the MELODY phase 3 randomized trial, nirsevimab reduced RSV-associated medically attended lower respiratory tract infections (MA-LRTIs) and RSV coinfections in infants entering their first RSV season. – No evidence was found for replacement of RSV infection by other respiratory viruses following nirsevimab immunization. – Most RSV-associated LRTIs adjudicated in the trial were mild; hospitalization occurred in roughly one-quarter of single RSV infections.
Background: clinical context and unmet need
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
